REDWOOD CITY, Calif.,
Sept. 28, 2016 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
the company will present results from nine studies at the European
Society for Medical Oncology (ESMO) 2016 Congress, which will take
place October 7-11 at the Bella
Center in Copenhagen, Denmark. The
results will include:
- Analytical validation study results for the recently launched
Oncotype SEQ™ Liquid Select test. Oncotype SEQ is the first
non-invasive liquid biopsy test that the company is delivering
through its Oncotype IQ™ Genomic Intelligence Platform.
- Two presentations highlighting updated prospective outcomes
from a large population-based observational study based on the
Surveillance, Epidemiology, and End Results (SEER) program of the
National Cancer Institute (NCI). The primary SEER Registry
study results, published in Nature Partner Journals Breast
Cancer, demonstrated that the Oncotype DX® Breast
Recurrence Score™ accurately predicted prospective patient outcomes
in more than 44,500 patients, including those with node-negative
and node-positive breast cancer. The updated results to be
presented at ESMO will include an additional year of patient data
and an additional year of follow-up for patients included in the
original study.
- New prospective outcomes data on the Oncotype DX Breast
Recurrence Score from a multi-center study in node-positive disease
from Clalit Health Services, the largest health maintenance
organization in Israel.
- Five international studies demonstrating the value of the
Oncotype DX Breast Recurrence Score on treatment decisions in
Canada, the Czech Republic, Italy and Spain. These studies include new prospective
clinical utility evidence for node-positive disease and results on
the clinical impact of Oncotype DX beyond immunohistochemistry for
Ki-67.
The ESMO abstracts are now available at www.esmo.org. Following
are details for each presentation (all times are in Central
European Summer Time):
Friday, October 7
- Abstract: 146 O
Proffered Paper Session: "Outcome disparities by age and
21-gene recurrence score® (RS) result in hormone receptor positive
(HR+) breast cancer (BC)"
Author: S. Shak, M.D.
Location: Stockholm
Time: 16:00 – 17:30
Saturday, October 8
- Abstract: 147 PD
Poster Discussion Session: "First
prospectively-designed outcome study in estrogen receptor (ER)+
breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes
in whom treatment decisions in clinical practice incorporated the
21-gene Recurrence Score result"
Authors: S. Stemmer, M.D.
Location: Berlin
Time: 15:00 – 16:00
- Abstract: 150 PD
Poster Discussion Session: "Breast cancer-specific survival
in >4,600 patients with lymph node-positive (LN+) hormone
receptor-positive (HR+) invasive breast cancer (BC) and 21-gene
Recurrence Score (RS) results in the SEER registries"
Authors: D.P. Miller
Location: Berlin
Time: 15:00 – 16:00
Monday, October 10
- Abstract: 175 P
Poster Display: "First prospective multicenter Italian study
on the impact of the 21-gene Recurrence Score (RS) in adjuvant
clinical decisions for ER+/HER2- early breast cancer patients"
Author: M.V. Dieci
Location: Hall E
Session Time: 13:00 – 14:00
- Abstract: 181 P
Poster Display: "Budget impact analysis of the 21-gene assay
(Oncotype DX Breast Cancer) for the breast cancer treatment in the
Basque country"
Author: Toribio, M.D.
Location: Hall E
Session Time: 13:00 – 14:00
- Abstract: 177 P
Poster Display: "The impact of the 21-gene assay in the
Czech Republic on adjuvant
chemotherapy (CT) recommendations and costs in estrogen receptor
positive (ER+) early stage breast cancer (ESBC) patients with grade
2 tumors and risk factors"
Author: K. Petrakova, M.D., Ph.D.
Location: Hall E
Session Time: 13:00 – 14:00
- Abstract: 180 P
Poster Display: "Use of Oncotype DX Recurrence Score (RS)
reduces chemotherapy (CT) beyond treatment decisions using
Ki67-based determinations of luminal A and B breast cancer
subtypes: A retrospective study in the Spanish population"
Author: L. Garcia-Estevez,
M.D.
Location: Hall E
Session Time: 13:00 – 14:00
- Abstract: 183 P
Poster Display: "Prospective evaluation of the impact of the
21-gene Recurrence Score assay on adjuvant treatment decisions for
women with node-positive breast cancer in Ontario, Canada"
Author: S. Torres, M.D.
Location: Hall E
Session Time: 13:00 – 14:00
- Abstract: 1162 P
Poster Display: "Analytical performance of a new liquid
biopsy mutation panel for detection of clinically actionable
variants"
Author: C. Svedman, M.D.
Location: Hall E
Session Time: 13:00 – 14:00
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. With
more than 600,000 patients tested in more than 90 countries, the
Oncotype DX tests have redefined personalized medicine by making
genomics a critical part of cancer diagnosis and treatment. To
learn more about Oncotype DX tests, visit www.OncotypeDX.com,
www.mybreastcancertreatment.org
and www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care by addressing the
overtreatment of the disease, one of the greatest issues in
healthcare today. With its Oncotype IQ™ Genomic Intelligence
Platform, the company is applying its world-class scientific and
commercial expertise and infrastructure to lead the translation of
clinical and genomic big data into actionable results for
treatment planning throughout the cancer patient journey, from
diagnosis to treatment selection and monitoring. The Oncotype
IQ portfolio of genomic tests and services currently consists of
the company's flagship line of Oncotype DX gene expression tests
that have been used to guide treatment decisions for more than
600,000 cancer patients worldwide. Genomic Health is
expanding its test portfolio to include additional liquid- and
tissue-based tests, including the recently launched Oncotype SEQ™
Liquid Select assay. The company is based in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties are set forth in
our filings with the Securities and Exchange Commission, including
in our quarterly report on Form 10-Q for the quarter ended
June 30, 2016. These forward-looking
statements speak only as of the date hereof. Genomic Health
disclaims any obligation to update these forward-looking
statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ and Oncotype IQ are
trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-B
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-reinforces-global-leadership-in-genomic-based-diagnostics-with-presentation-of-nine-personalized-medicine-studies-conducted-in-six-countries-at-esmo-2016-congress-300335377.html
SOURCE Genomic Health, Inc.